Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study

Journal of Hepatology

Volumn 61, Issue 2, 2014, Pages 228-234

  Younossi, Zobair M ^a,b   Stepanova, Maria ^a,b   Zeuzem, Stefan ^c   Dusheiko, Geoffrey ^d   Esteban, Rafael ^e   Hezode, Christophe ^f   Reesink, Hendrik W ^g   Weiland, Ola ^h   Nader, Fatema ^a   Hunt, Sharon L ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HENRI MONDOR HOSPITAL   (France)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CLDQ HCV; Clinical trial; FACIT F; Hepatitis C; Patient reported outcomes; SF 36; WPAI

Indexed keywords

INTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADULT; ANEMIA; ARTICLE; CHRONIC LIVER DISEASE QUESTIONNAIRE HCV; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEPRESSION; EMOTION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SINGLE BLIND PROCEDURE; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; WELLBEING; WORK PRODUCTIVITY AND ACTIVITY INDEX SPECIFIC HEALTH PROBLEM; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE;

EID: 84904730054     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.04.003     Document Type: Article

References (24)

1. B. Hajarizadeh, J. Grebely, and G.J. Dore Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 10 2013 553 562
2. J. Vietri, G. Prajapati, and A.C. El Khoury The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries BMC Gastroenterol 13 2013 16
3. Z.M. Younossi, and M. Stepanova Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States Clin Gastroenterol Hepatol 8 2010 718 723
4. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
5. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
6. Z. Younossi, J. Kallman, and J. Kincaid The effects of HCV infection and management on health-related quality of life Hepatology 45 2007 806 816
7. R.A. Brook, N.L. Kleinman, J. Su, P.K. Corey-Lisle, and U.H. Iloeje Absenteeism and productivity among employees being treated for hepatitis C Am J Manag Care 17 2011 657 664
8. J.G. McHutchison, J.E. Ware, M.S. Bayliss, S. Pianko, J.K. Albrecht, and S. Cort et al. The effects of interferon alpha 2-b in combination with ribavirin and health related quality of life and productivity J Hepatol 34 2001 140 147
9. T. Hassanein, G. Cooksley, M. Sulkowski, C. Smith, G. Marinos, and M.Y. Lai et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C J Hepatol 40 2004 675 681
10. Z.M. Younossi, M.E. Singer, H.M. Mir, L. Henry, and S. Hunt Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients J Hepatol 60 2014 530 537
11. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, and E. Lawitz et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C Clin Gastroenterol Hepatol 2013 10.1016/j.cgh.2013.11.032
12. Z.M. Younossi, M. Stepanova, L. Henry, E. Gane, I.M. Jacobson, and E. Lawitz et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C) J Hepatol 60 2014 741 747
13. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
14. S. Zeuzem, G. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R. Hyland et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology 58 2013 1085
15. R.D. Hays, and L.S. Morales The RAND-36 measure of health-related quality of life Ann Med 33 2001 350 357
16. D.F. Cella, D.S. Tulsky, G. Gray, B. Sarafian, E. Linn, and A. Bonomi et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
17. K. Webster, L. Odom, A. Peterman, L. Lent, and D. Cella The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire Qual Life Res 8 1999 604
18. Z.M. Younossi, G. Guyatt, M. Kiwi, N. Boparai, and D. King Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease Gut 45 1999 295 300
19. M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument PharmacoEconomics 4 1993 353 365
20. D.M. Evon, D.A. Esserman, J.E. Bonner, T. Rao, M.W. Fried, and C.E. Golin Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence J Viral Hepat 20 2013 536 549
21. Z.M. Younossi, M. Stepanova, M. Afendy, B.P. Lam, and A. Mishra Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C J Viral Hepat 20 2013 550 555
22. C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
23. Z.M. Younossi, F.H. Nader, C. Bai, R. Sjogren, J.P. Ong, and R. Collantes et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment J Viral Hepat 15 2008 370 378
24. A.A. John-Baptiste, G. Tomlinson, P.C. Hsu, M. Krajden, E.J. Heathcote, and A. Laporte et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C Am J Gastroenterol 104 2009 2439 2448